GlassScriptPhysician profile
Dharamvir Jain
NPI 1417938234
$3,402.19
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.77 · 2020: $12.45 · 2021: $431 · 2022: $2,287 · 2023: $448 · 2024: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.55 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,718.39 | 2022 | |
| Daiichi Sankyo INC. | $576.02 | 2022-2023 | Enhertu |
| Covis Pharma Gmbh | $400.00 | 2021 | |
| Gilead Sciences, INC. | $245.93 | 2021-2023 | Trodelvy |
| Astrazeneca Uk Limited | $135.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Medtronic, INC. | $82.20 | 2024 | Azure Xt Dr Mri Surescan |
| Pfizer INC. | $25.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $19.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.77 | 2019 | |
| Amgen INC. | $15.63 | 2023 | Xgeva, Vectibix, Nplate |
| Tactile Systems Technology INC | $12.69 | 2023 | Entre Plus, Flexitouch Plus |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharamvir Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.